{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T14:40:29Z","timestamp":1781534429380,"version":"3.54.5"},"reference-count":42,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T00:00:00Z","timestamp":1642118400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003710","name":"Korea Health Industry Development Institute","doi-asserted-by":"publisher","award":["HI17C1095"],"award-info":[{"award-number":["HI17C1095"]}],"id":[{"id":"10.13039\/501100003710","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","award":["2019R1A2C1002863"],"award-info":[{"award-number":["2019R1A2C1002863"]}],"id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biomedicines"],"abstract":"<jats:p>Immune checkpoint inhibitors and tyrosine kinase inhibitors are the first-line treatment for metastatic renal cell carcinoma (mRCC), but their benefits are limited to specific patient subsets. Here, we aimed to evaluate the therapeutic efficacy of JX-594 (pexastimogene devacirepvec, Pexa-vec) monotherapy by systemic injection in comparison with sunitinib monotherapy in metastatic orthotopic RCC murine models. Two highly metastatic orthotopic RCC models were developed to compare the treatment efficacy in the International Metastatic RCC Database Consortium favorable-risk and intermediate- or poor-risk groups. JX-594 was systemically injected through the peritoneum, whereas sunitinib was orally administered. Post-treatment, tumor microenvironment (TME) remodeling was determined using immunofluorescence analysis. Systemic JX-594 monotherapy injection demonstrated therapeutic benefit in both early- and advanced-stage mRCC models. Sunitinib monotherapy significantly reduced the primary tumor burden and number of lung metastases in the early-stage, but not in the advanced-stage mRCC model. Systemic JX-594 delivery remodeled the primary TME and lung metastatic sites by increasing tumor-infiltrating CD4\/8+ T cells and dendritic cells. Systemic JX-594 monotherapy demonstrated significantly better therapeutic outcomes compared with sunitinib monotherapy in both early- and advanced-stage mRCCs by converting cold tumors into hot tumors. Sunitinib monotherapy effectively suppressed primary tumor growth and lung metastasis in early-stage mRCC.<\/jats:p>","DOI":"10.3390\/biomedicines10010173","type":"journal-article","created":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T12:34:04Z","timestamp":1642163644000},"page":"173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Systemic Injection of Oncolytic Vaccinia Virus Suppresses Primary Tumor Growth and Lung Metastasis in Metastatic Renal Cell Carcinoma by Remodeling Tumor Microenvironment"],"prefix":"10.3390","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9976-6599","authenticated-orcid":false,"given":"Jee Soo","family":"Park","sequence":"first","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"},{"name":"Department of Urology, Sorokdo National Hospital, Goheung 59562, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myung Eun","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0381","authenticated-orcid":false,"given":"Won Sik","family":"Jang","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongchan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"},{"name":"Department of Urology, Yongin Severance Hospital, Yonsei University Health System, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Se Mi","family":"Park","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keunhee","family":"Oh","sequence":"additional","affiliation":[{"name":"Research Center, SillaJen, Inc., Seoul 07325, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5009-3696","authenticated-orcid":false,"given":"Namhee","family":"Lee","sequence":"additional","affiliation":[{"name":"Research Center, SillaJen, Inc., Seoul 07325, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2246-8838","authenticated-orcid":false,"given":"Won Sik","family":"Ham","sequence":"additional","affiliation":[{"name":"Department of Urology, Urological Science Institute, College of Medicine, Yonsei University, Seoul 03722, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,1,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.eururo.2010.10.029","article-title":"Age-Adjusted Incidence, Mortality, and Survival Rates of Stage-Specific Renal Cell Carcinoma in North America: A Trend Analysis","volume":"59","author":"Sun","year":"2011","journal-title":"Eur. Urol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.ctrv.2007.12.001","article-title":"Epidemiologic and socioeconomic burden of metastatic renal cell carcinoma (mRCC): A literature review","volume":"34","author":"Gupta","year":"2008","journal-title":"Cancer Treat. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/nrurol.2011.43","article-title":"What can molecular pathology contribute to the management of renal cell carcinoma?","volume":"8","author":"Stewart","year":"2011","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.ccell.2015.03.001","article-title":"Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy","volume":"27","author":"Topalian","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e000857","DOI":"10.1136\/jitc-2020-000857","article-title":"Oncolytic vaccinia virus reinvigorates peritoneal immunity and cooperates with immune checkpoint inhibitor to suppress peritoneal carcinomatosis in colon cancer","volume":"8","author":"Lee","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1002\/cam4.4130","article-title":"Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era","volume":"10","author":"Numakura","year":"2021","journal-title":"Cancer Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/PPO.0000000000000471","article-title":"The immunotherapy revolution in kidney cancer treatment: Scientific rationale and first-generation results","volume":"26","author":"Hasanov","year":"2020","journal-title":"Cancer J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1056\/NEJMoa1816714","article-title":"Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Rini","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1056\/NEJMoa1816047","article-title":"Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma","volume":"380","author":"Motzer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Oh, C.-M., Chon, H.J., and Kim, C. (2020). Combination Immunotherapy Using Oncolytic Virus for the Treatment of Advanced Solid Tumors. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21207743"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","article-title":"Therapeutic Targeting of the Tumor Microenvironment","volume":"11","author":"Bejarano","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1039\/D0BM01183E","article-title":"Immunostimulatory biomaterials to boost tumor immunogenicity","volume":"8","author":"Stokes","year":"2020","journal-title":"Biomater. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Xiao, B., Zhang, L., Liu, H., Fang, H., Wang, C., Huang, B., Liu, X., Zhou, X., and Wang, Y. (2020). Oncolytic Adenovirus CD55-Smad4 Suppresses Cell Proliferation, Metastasis, and Tumor Stemness in Colorectal Cancer by Regulating Wnt\/\u03b2-Catenin Signaling Pathway. Biomedicines, 8.","DOI":"10.3390\/biomedicines8120593"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1038\/nm.3089","article-title":"Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer","volume":"19","author":"Heo","year":"2013","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1158\/1078-0432.CCR-18-1932","article-title":"Tumor microenvironment remodeling by intratumoral oncolytic vaccinia virus enhances the efficacy of immune checkpoint blockade","volume":"25","author":"Chon","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/mt.2014.243","article-title":"Phase 1 Study of Intratumoral Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus, in Pediatric Cancer Patients","volume":"23","author":"Cripe","year":"2015","journal-title":"Mol. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"TPS4146","DOI":"10.1200\/JCO.2016.34.15_suppl.TPS4146","article-title":"PHOCUS: A phase 3 randomized, open-label study comparing the oncolytic immunotherapy Pexa-Vec followed by sorafenib (SOR) vs SOR in patients with advanced hepatocellular carcinoma (HCC) without prior systemic therapy","volume":"34","author":"Galle","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1158\/0008-5472.CAN-12-2687","article-title":"Oncolytic Vaccinia Virus Disrupts Tumor-Associated Vasculature in Humans","volume":"73","author":"Breitbach","year":"2013","journal-title":"Cancer Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1038\/mt.2010.183","article-title":"Efficacy and Safety\/Toxicity Study of Recombinant Vaccinia Virus JX-594 in Two Immunocompetent Animal Models of Glioma","volume":"18","author":"Lun","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"bio058566","DOI":"10.1242\/bio.058566","article-title":"Development of a highly pulmonary metastatic orthotopic renal cell carcinoma murine model","volume":"10","author":"Park","year":"2021","journal-title":"Biol. Open"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nri.2016.134","article-title":"Mechanisms of immunomodulation by mammalian and viral decoy receptors: Insights from structures","volume":"17","author":"Felix","year":"2017","journal-title":"Nat. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/j.ymthe.2018.04.001","article-title":"Oncolytic Virus Combination Therapy: Killing One Bird with Two Stones","volume":"26","author":"Martin","year":"2018","journal-title":"Mol. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/nrd4663","article-title":"Oncolytic viruses: A new class of immunotherapy drugs","volume":"14","author":"Kaufman","year":"2015","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/1476-4598-12-103","article-title":"Oncolytic viruses as therapeutic cancer vaccines","volume":"12","author":"Bartlett","year":"2013","journal-title":"Mol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: First in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Rha, S.Y., Merchan, J., Oh, S.Y., Kim, C., Bae, W.K., Lee, H.W., Dillon, M., Deering, R., Kroog, G., and Ha, K.S. (2020, January 22\u201324). Abstract CT121: A phase Ib study of recombinant vaccinia virus in combination with immune checkpoint inhibition (ICI) in advanced renal cell carcinoma (RCC). Proceedings of the AACR Annual Meeting, Philadelphia, PA, USA.","DOI":"10.1158\/1538-7445.AM2020-CT121"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.eururo.2019.05.041","article-title":"Safe Use of Immune Checkpoint Inhibitors in the Multidisciplinary Management of Urological Cancer: The European Association of Urology Position in 2019","volume":"76","author":"Grimm","year":"2019","journal-title":"Eur. Urol."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Schirrmacher, V. (2020). Cancer Vaccines and Oncolytic Viruses Exert Profoundly Lower Side Effects in Cancer Patients than Other Systemic Therapies: A Comparative Analysis. Biomedicines, 8.","DOI":"10.3390\/biomedicines8030061"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Guo, Z.-S. (2021). Oncolytic Virus Immunotherapy: Showcasing Impressive Progress in Special Issue II. Biomedicines, 9.","DOI":"10.3390\/biomedicines9060663"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.ymthe.2006.05.008","article-title":"Systemic Armed Oncolytic and Immunologic Therapy for Cancer with JX-594, a Targeted Poxvirus Expressing GM-CSF","volume":"14","author":"Kim","year":"2006","journal-title":"Mol. Ther."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Laruelle, A., Manini, C., I\u00f1arra, E., and L\u00f3pez, J. (2021). Metastasis, an Example of Evolvability. Cancers, 13.","DOI":"10.3390\/cancers13153653"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.21873\/anticanres.15301","article-title":"CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma","volume":"41","author":"Sekino","year":"2021","journal-title":"Anticancer. Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.eururo.2021.04.042","article-title":"The 2021 Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Immune Checkpoint Inhibitor\u2013based Combination Therapies for Treatment-naive Metastatic Clear-cell Renal Cell Carcinoma Are Standard of Care","volume":"80","author":"Bedke","year":"2021","journal-title":"Eur. Urol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.6004\/jnccn.2020.0043","article-title":"NCCN Guidelines Insights: Kidney Cancer, Version 1.2021","volume":"18","author":"Motzer","year":"2020","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e1105","DOI":"10.1016\/S2666-1683(20)33322-X","article-title":"Real-world clinical effectiveness of second-line sunitinib following immuno-oncology therapy in patients with metastatic renal cell carcinoma","volume":"19","author":"Wells","year":"2020","journal-title":"Eur. Urol. Open Sci."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"5839","DOI":"10.1158\/1078-0432.CCR-16-0143","article-title":"Repurposing Sunitinib with Oncolytic Reovirus as a Novel Immunotherapeutic Strategy for Renal Cell Carcinoma","volume":"22","author":"Lawson","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/s41571-021-00496-y","article-title":"Anti-angiogenic agents\u2014Overcoming tumour endothelial cell anergy and improving immunotherapy outcomes","volume":"18","author":"Huinen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e002922","DOI":"10.1136\/jitc-2021-002922","article-title":"Eosinophilic features in clear cell renal cell carcinoma correlate with outcomes of immune checkpoint and angiogenesis blockade","volume":"9","author":"Yoshida","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Park, J., Lee, M., Jang, W., Rha, K., Lee, S., Lee, J., and Ham, W. (2021). The DEAD\/DEAH Box Helicase, DDX11, Is Essential for the Survival of Advanced Clear Cell Renal Cell Carcinoma and Is a Determinant of PARP Inhibitor Sensitivity. Cancers, 13.","DOI":"10.3390\/cancers13112574"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/j.intimp.2011.01.030","article-title":"MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy","volume":"11","author":"Finke","year":"2011","journal-title":"Int. Immunopharmacol."}],"container-title":["Biomedicines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T14:02:25Z","timestamp":1760364145000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2227-9059\/10\/1\/173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,14]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["biomedicines10010173"],"URL":"https:\/\/doi.org\/10.3390\/biomedicines10010173","relation":{},"ISSN":["2227-9059"],"issn-type":[{"value":"2227-9059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,14]]}}}